Physician profile
Christopher D Boston
NPI 1295932390
$6,334.49
in general payments reported to CMS, 2019-2025
41 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $676 · 2021: $600 · 2022: $332 · 2023: $872 · 2024: $1,579 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,837 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.76 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,118.71 | 2019-2025 | |
| Abbvie INC. | $938.24 | 2019-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $898.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $562.45 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $382.12 | 2019-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $363.93 | 2019-2021 | |
| Glaxosmithkline, LLC. | $220.57 | 2022-2025 | Shingrix, Boostrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.01 | 2019-2025 | Ofev |
| Inspire Medical Systems, INC. | $169.96 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $153.75 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Cequr Corporation | $120.00 | 2024 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.53 | 2020-2025 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $115.07 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.82 | 2020-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $78.15 | 2020-2024 | Airsupra |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $72.43 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $67.94 | 2023 | Nexletol, Contrave, Onzetra Xsail |
| Phathom Pharmaceuticals, INC. | $67.23 | 2024-2025 | Voquezna |
| Abbott Laboratories | $60.08 | 2025 | Proclaim, Freestyle Libre 3 |
| Eisai INC. | $46.58 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.58 | 2024-2025 | Caplyta |
| Nalpropion Pharmaceuticals LLC | $38.52 | 2019 | |
| Inari Medical, INC. | $34.44 | 2024-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sanofi-Aventis U.S. LLC | $30.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.94 | 2023 | Xarelto |
| Exact Sciences Corporation | $28.90 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $20.65 | 2024 | Vyepti |
| Boston Scientific Corporation | $20.07 | 2025 | Wavewriter Alpha Prime 16 |
| Corium, LLC | $18.89 | 2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $18.35 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.33 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $17.66 | 2025 | Austedo Xr |
| Genentech USA, INC. | $17.12 | 2019 | |
| Medtronic, INC. | $17.11 | 2025 | Vanta Adaptivestim |
| Ibsa Pharma INC. | $16.41 | 2023 | Tirosint, Licart |
| Shield Therapeutics INC | $15.59 | 2023 | Accrufer |
| Supernus Pharmaceuticals, INC. | $15.38 | 2025 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $15.26 | 2020 | |
| Adlon Therapeutics L.P. | $15.06 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.46 | 2024 | Nuzyra |
| Allergan, INC. | $11.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Boston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.